Julie Refardt, Cornelia Imber, Clara O Sailer, Nica Jeanloz, Laura Potasso, Alexander Kutz, Andrea Widmer, Sandrine A Urwyler, Fahim Ebrahimi, Deborah R Vogt, Bettina Winzeler, Mirjam Christ-Crain
BACKGROUND: Treatment options to address the hyponatremia induced by the syndrome of inappropriate antidiuresis (SIAD) are inadequate. The sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin promotes osmotic diuresis via urinary glucose excretion and therefore, might offer a novel treatment option for SIAD. METHODS: In this double-blind, randomized trial, we recruited 88 hospitalized patients with SIAD-induced hyponatremia <130 mmol/L at the University Hospital Basel from September 2016 until January 2019 and assigned patients to receive, in addition to standard fluid restriction of <1000 ml/24 h, a once-daily dose of oral empagliflozin or placebo for 4 days...
March 2020: Journal of the American Society of Nephrology: JASN